Turnstone Biologics CORP 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
Turnstone Biologics Corp. discontinues clinical studies and explores strategic alternatives to enhance stockholder value amid financial constraints and Nasdaq compliance challenges.
Turnstone Biologics' 10-K filing details its common stock structure, ongoing clinical trials for its Selected TIL therapies, and future development plans.